Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of
cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Rationale: Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin
II receptor blockers) is a major concern for clinicians treating coronavirus disease 2019 …

Acute decompensated heart failure (ADHF) is one of the leading admission diagnoses
worldwide, yet it is an entity with incompletely understood pathophysiology and limited …

Inflammation has been recognized as a major pathophysiological contributor to the entire
spectrum of human heart failure (HF), including HF with reduced ejection fraction, HF with …

ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Importance Clinical guidelines for the early management of acute heart failure in the
emergency department (ED) setting are based on only moderate levels of evidence, with …

Volume recruitment from the splanchnic compartment is an important physiological
response to stressors such as physical activity and blood loss. In the setting of heart failure …